Previous Speakers

PARTNERS


SHORTWAVE is a pre-clinical stage biotech company focused on the development of IP-protected formulations and delivery methods of psychedelics-based medicine to treat mental illness, chronic pain and neuro degenerative diseases.

Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognised scientists, on a mission to create safe and effective therapeutics for patients.

COMPASS is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first programme is researching how COMP360 psilocybin therapy could help people with treatment-resistant depression.

Negev Capital is a psychedelic medical intervention investment fund with assets of over USD$30+ million. The Company invests in drug discovery, with a focus on pre-clinical and/or Phase 1 stages of development.

Clerkenwell Health is Europe’s leading psychedelic specialty CRO offering trial design, regulatory submission, and trial delivery services. Addressing the growing unmet demand for effective mental health treatments.

FTI Consulting has built an unrivalled, global strategic communications offering to life science and healthcare companies. We design and execute communication programmes to protect and promote reputation, enhance stakeholder engagement and build a premium valuation.


Beautiful Space is Europes leading innovation in psychedelic-assisted couples therapy. Their official collaboration with Imperial College London will recruit 20 couples later this year.

Official Workshop

Official Patient Group

PsyPAN is a non-profit organisation created to connect and empower all psychedelic participants, whether they are taking part in clinical trials or receiving therapy at the various legal treatment centres being set up globally.

MEDIA PARTNERS


EVENT PARTNERSHIP

Partnering with PSYCH enables organisations to engage an audience ready to support the development of psychedelic healthcare, such as researchers, regulators and investors.

Our PURPOSE

Against the backdrop of a deepening mental health crisis, psychedelic medicines have demonstrated safety and efficacy in clinical trials.

To promote their groundbreaking potential, experts from the life sciences industry present their research at PSYCH Symposium: London.

WHY LONDON?

The UK is home to world-leading psychedelic research institutions and publicly traded companies, with direct access to London’s capital markets. This lays the foundations for a flourishing domestic industry, with the PSYCH Symposium championing the emerging ecosystem.